CRISPR News

Explore how CRISPR screening improves CAR-T and CAR-NK therapies by enhancing persistence and overcoming tumor microenvironment challenges.

Explore advancements in NK cell engineering for cancer therapies from Dr. Rezvani’s lab as presented at AACR.

Traditional autologous CAR-T therapies, which rely on patient-derived T cells, face significant limitations, including lengthy manufacturing times, high costs, and variability in cell quality, particularly for patients with

Synthetic RNA vaccines and therapeutics are frequently delivered via LNPs; therefore, technologies enabling nanoparticle characterization are needed to ensure their efficacy and safety.

As presented at ASGCT 2023 several innovative approaches leveraging antibody-conjugated AAVs, shuttle peptides, and viral-like particles are making possible the targeted delivery of gene and editing cargo in vivo.

The success of cancer immunotherapies, such as CAR T cells for targeting tumor cells in hematological malignancies, has spurred an unprecedented push to develop more and improved living drugs.

Learn how CRISPR screens, such as knock-out, knock-in, CRISPRa, and CRISPRi, are helping to identify molecular factors and programs critical for developing effective cell therapies.

Learn how a new T cell receptor, HIT, engineered by Dr. Michel Sadelain’s group achieves greater sensitivity for tumor antigens than CARs.

Learn how CRISPR/Cas9 editing tools support precise mlo gene editing to develop plant varieties resistant to common fungal diseases such as powdery mildew while retaining growth potential and productivity.

CRISPR/Cas9 enables targeted genomic insertions, clearing the way for precise therapies for cancer, rare diseases, and more.